Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Amazingly….
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(313)
•••
Comment by beenthereon Feb 19, 2022 10:08pm
88 Views
Post# 34445706

RE:RE:RE:RE:RE:RE:RE:RE:Amazingly….

RE:RE:RE:RE:RE:RE:RE:RE:Amazingly….I'm going to step in here and give you my opinion.

First I have to agree with Finally and others but ..

I have been temped to get out of this even with a 80% plus loss but ...

.. but part of me is saying what if .. what if ...

.. what if these guys are correct and the real issue was management abilities say like RH (who was happy to  keep the status quo and have a job)  or Day ( who was never committed) or DrDR ( who just doesn't have the ability)

What if JD and chrispi  were right?   To be honest I really am not sure but  I would think ( gamble) BTI's IP is possibly worth more than 25 cents so for that reason I'm sticking around ( after 8 years plus) for a while longer!

Never thought  I would be saying this but BTI may be worth more to me ( us) if bought out! For sure 25 cents is not acceptable!


so lovingold just like you did with Finally  answer my question! Who did you go by on SH before?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities